Published in Virus Weekly, June 13th, 2006
Study 1: Researchers from Japan reported that hepatocellular carcinogenesis (HCC) is reduced by long-term glycyrrhizin injection therapy in patients with interferon (IFN)-resistant active chronic hepatitis C.
"To elucidate the influence of a glycyrrhizin therapy on hepatocarcinogenesis rate in IFN-resistant hepatitis C, we retrospectively analyzed 1249 patients with chronic hepatitis with or without cirrhosis," wrote K. Ikeda and colleagues, Toranomon General Hospital.
They continued, "Among 346 patients with high Ala transaminase value (twice or more of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.